(19)

(11)

EP 4 583 871 A1

(12)

(43) Date of publication: 16.07.2025 Bulletin 2025/29 (21) Application number: 23864083.3 (22) Date of filing: 11.09.2023

(51) International Patent Classification (IPC):  A61K 31/395(2006.01) A61K 31/4164(2006.01) A61K 31/41(2006.01) A61K 31/33(2006.01) (52) Cooperative Patent Classification (CPC): A61K 31/4174; A61K 9/006 (86) International application number: PCT/US2023/073874 (87) International publication number: WO 2024/055042 (14.03.2024 Gazette 2024/11)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: KH MA MD TN (30) Priority: 11.09.2022 US 202263405452 P 24.05.2023 US 202363504109 P (71) Applicant: BioXcel Therapeutics, Inc. New Haven, CT 06511 (US)	(72) Inventors: DE VIVO, Michael New Haven, Connecticut 06511 (US) RAJACHANDRAN, Lavanya New Haven, Connecticut 06511 (US) RISINGER, Rob New Haven, Connecticut 06511 (US) KOELLER, Hajira New Haven, Connecticut 06511 (US) (74) Representative: Cooley (UK) LLP  22 Bishopsgate London EC2N 4BQ London EC2N 4BQ (GB)